Real-World Lung Cancer Outcomes With Targeted Drug Therapy in China
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (NSCLC), which is a common type of lung cancer
- Your cancer was stage IB, II, or III (early-to-mid stage) at the time of diagnosis
- You had surgery to remove the cancer
- Your cancer has an EGFR mutation (a specific genetic change that makes it respond to targeted drugs)
- You started taking an EGFR-TKI drug (a targeted therapy pill) after surgery, between July 2023 and June 2026, to help prevent cancer recurrence
- You received treatment in China
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world information about people with lung cancer who get newer kinds of cancer drugs. It aims to understand how these innovative therapies work in everyday care and help future research.
This trial tests whether using a blood test (ctDNA) to guide targeted therapy after surgery can improve outcomes for patients with stage II-IIIA non-small cell lung cancer that has an EGFR mutation. If you qualify, you may receive a targeted pill (osimertinib) based on your ctDNA results.
This study looks back at the medical records of people in China diagnosed with early-stage lung cancer (Stage I–III) to learn more about the disease and how it is treated. It does not involve any new treatments or tests—just reviewing information that was already collected during your care.
This trial studies how Traditional Chinese Medicine (TCM) patterns relate to the effectiveness of targeted pills (EGFR-TKIs) in lung cancer. It is for people with EGFR-mutated non-small cell lung cancer who are about to start or are already on this type of treatment.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.